SlidesetTuberculosisLung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. KempkerView Slideset
SlidesetRifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmDView Slideset
SlidesetTuberculosisEarly interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. HeysellView Slideset
SlidesetTuberculosisSub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. GuiastrennecView Slideset
SlidesetTuberculosisA Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. AljayyoussiView Slideset
SlidesetTuberculosisDevelopment of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. GardnerView Slideset
SlidesetTuberculosisApplication Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. HatleyView Slideset
SlidesetTuberculosisThe relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. DooleyView Slideset
SlidesetTuberculosisA translational modelling and simulations approach to exploit pre-clinical tuberculosis data | S. WichaView Slideset
SlidesetTuberculosisSimulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling | R. RajoliView Slideset
SlidesetTuberculosisLong acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Slideset
SlidesetTuberculosisRifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection | H. BlumbergView Slideset
SlidesetTuberculosisHigh drug tolerance of Mycobacterium tuberculosis in caseum | J. SarathyView Slideset
SlidesetTuberculosisExploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling | A. SchipaniView Slideset
SlidesetTuberculosisA model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. SvenssonView Slideset
SlidesetTuberculosisA new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Slideset
SlidesetTuberculosisPopulation Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. PeloquinView Slideset
SlidesetTuberculosisPopulation pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. SvenssonView Slideset
SlidesetTuberculosisRifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhDView Slideset
SlidesetTuberculosisPharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. ImperialView Slideset
